Medtronic's Hugo Surgery Platform Approved in U.S.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 08 2026
0mins
Source: NASDAQ.COM
- FDA Approval Milestone: Medtronic's Hugo robotic-assisted surgery platform received FDA approval for urologic procedures in December 2025, marking the company's official entry into the robotic surgery market, despite facing strong competition from Intuitive Surgical.
- Significant Market Potential: With approximately 230,000 related surgeries performed annually in the U.S., the approval opens up a substantial market opportunity for Medtronic, as the robotic surgery market is projected to grow from $13.8 billion last year to $63.7 billion by 2035.
- Accelerated Growth Rate: Medtronic's CEO disclosed during the Q4 2026 earnings call that procedure volumes for Hugo are growing two to three times faster than the market, indicating strong growth potential despite starting from a small base, which could lead to increased market share in the future.
- Global Deployment Advantage: The Hugo system is already in use in over 35 countries, with hospitals having performed tens of thousands of procedures; while it may not surpass Intuitive Surgical's market position, Medtronic's diversified healthcare product portfolio provides a solid foundation to capture opportunities in the rapidly growing robotic surgery market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDT
Wall Street analysts forecast MDT stock price to rise
20 Analyst Rating
11 Buy
9 Hold
0 Sell
Moderate Buy
Current: 80.200
Low
102.00
Averages
111.76
High
120.00
Current: 80.200
Low
102.00
Averages
111.76
High
120.00
About MDT
Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Medtronic Acquires Scientia Vascular for $550 Million
- Acquisition Deal Size: Medtronic has acquired medical device company Scientia Vascular for $550 million, including potential milestone payments, which further strengthens its neurovascular portfolio.
- Technological Integration Advantage: The acquisition incorporates Scientia's guidewire and catheter technologies into Medtronic's product line, aiming to improve access in complex cerebral vasculature, thereby enhancing the efficiency of stroke and aneurysm procedures.
- Financial Impact Expectation: Medtronic anticipates that the deal will be minimally dilutive to adjusted earnings per share (EPS) in fiscal year 2027, with profitability expected to increase thereafter, indicating the strategic value of the acquisition.
- Market Reaction: Medtronic's shares closed at $80.20 on Friday, down 0.16%, but traded slightly higher at $80.26 in the overnight market, reflecting a cautiously optimistic market response to the acquisition.
See More
Boston Scientific Stock Price Decline Analysis
- Poor Stock Performance: Boston Scientific (BSX) shares have fallen over 50% year-to-date, reflecting market disappointment with its growth expectations, particularly as management has repeatedly lowered guidance, undermining investor confidence.
- Guidance Downgrade: The management has revised its 2026 organic revenue growth forecast down to between 6.5% and 8%, and has indicated flat revenue growth for Q2 and Q3, raising concerns about the company's long-term investment appeal amid declining procedure usage.
- Analyst Optimism: Despite the bearish market sentiment, 27 out of 31 analysts still rate the stock as a buy, with a consensus price target of $78 per share, indicating a potential upside of 65%, which reflects analysts' confidence in the company's recovery potential.
- Valuation Challenges: Boston Scientific currently trades at a mid-teen forward valuation, comparable to other medical device firms like Abbott and Medtronic, and achieving a premium valuation will likely require a faster-than-expected recovery in growth, which appears challenging in the current market environment.
See More
Boston Scientific Shares Plunge Over 50% Amid Guidance Cuts
- Significant Stock Decline: Boston Scientific (NYSE: BSX) shares have plummeted over 50% year-to-date, primarily due to the company's ongoing downward revisions of its full-year 2026 guidance, which has severely undermined investor confidence and elicited a negative market response.
- Performance Guidance Adjustments: Management initially projected organic sales growth of 10% to 11% in February, but after reporting a 19.5% growth for 2025, investor reactions were poor, leading to further reductions in April and May, with 2026 organic revenue guidance now set between 6.5% and 8%.
- Analyst Sentiment Remains Positive: Despite the bearish market sentiment, 27 out of 31 analysts covering the stock still rate it as a buy, with a consensus price target of $78 per share, indicating a potential upside of 65%, reflecting analysts' confidence in the company's recovery prospects.
- Valuation Challenges Ahead: Boston Scientific currently trades at a forward valuation in the mid-teens, comparable to other medical device firms like Abbott and Medtronic, and achieving a premium valuation will likely require a faster-than-expected recovery in growth, which remains uncertain pending upcoming Q2 results and guidance.
See More
Medtronic Acquires Scientia Vascular to Enhance Neurovascular Technology
- Acquisition Scale: Medtronic has acquired Scientia Vascular, a private medical device company in Salt Lake City, for $550 million, subject to customary adjustments and potential undisclosed earn-out and milestone payments, further solidifying Medtronic's market position in the neurovascular sector.
- Integration Advantages: Scientia's guidewires and catheters can be seamlessly integrated with Medtronic's existing neurovascular products, enhancing physician efficiency in treating complex neurovascular conditions, simplifying procedural workflows, and improving patient treatment experiences.
- Market Demand Alignment: With stroke being the third leading cause of death globally, Scientia's innovative access platform aims to improve navigability through complex anatomy, enabling physicians to reach occlusions or aneurysms more quickly, thereby enhancing the timeliness and success of treatments.
- Financial Impact Outlook: The acquisition is expected to be minimally dilutive to Medtronic's adjusted EPS in FY27 but accretive thereafter, demonstrating Medtronic's ongoing commitment to pursuing high-growth opportunities and enhancing value for physician and hospital partners.
See More
Medtronic Acquires Scientia Vascular to Enhance Neurovascular Technology
- Acquisition Scale: Medtronic has acquired Scientia Vascular for $550 million, subject to customary adjustments, with potential undisclosed earn-out and milestone payments, reflecting Medtronic's ongoing expansion strategy in the healthcare technology sector.
- Integration Advantage: Scientia's guidewires and catheters can be seamlessly integrated with Medtronic's existing neurovascular products, enhancing physician efficiency in treating complex neurovascular conditions and further solidifying Medtronic's market leadership in this field.
- Improved Treatment Efficiency: Scientia's novel access platform addresses challenges posed by complex anatomy by improving navigability and simplifying neurovascular procedures, enabling faster treatment delivery and reducing brain cell loss due to delayed therapy, which has significant clinical implications.
- Financial Impact Outlook: The acquisition is expected to have a minimal dilutive effect on Medtronic's adjusted EPS in FY27 but is projected to become accretive thereafter, indicating a strategic decision to pursue high-growth opportunities that enhance value for stakeholders.
See More
SpaceX Sets Record with $75 Billion IPO, Aiming for 25-30% Opening Pop
- Historic IPO: SpaceX is conducting a record-breaking IPO today, raising up to $75 billion, with expectations of a 25-30% opening pop, which could attract short-term investors and potentially destabilize the company's shareholder base.
- Market Reaction: Oil prices have dropped over 3% to below $85 per barrel due to optimism surrounding a potential peace deal between the U.S. and Iran, indicating market sentiment ahead of next week's G7 Summit.
- Executive Changes: Adobe announced that CFO Dan Durn is leaving to join Marvell; despite beating earnings expectations, Adobe's stock fell 7%, reflecting market concerns about slowing growth.
- Analyst Rating Changes: Citi upgraded AMD from hold to buy, anticipating that Meta will significantly increase its purchases of AMD chips, indicating AMD's strengthening position in the graphics processing unit market as a legitimate competitor to Nvidia.
See More
Medtronic Acquires Scientia Vascular for $550 Million
- Acquisition Deal Size: Medtronic has acquired medical device company Scientia Vascular for $550 million, including potential milestone payments, which further strengthens its neurovascular portfolio.
- Technological Integration Advantage: The acquisition incorporates Scientia's guidewire and catheter technologies into Medtronic's product line, aiming to improve access in complex cerebral vasculature, thereby enhancing the efficiency of stroke and aneurysm procedures.
- Financial Impact Expectation: Medtronic anticipates that the deal will be minimally dilutive to adjusted earnings per share (EPS) in fiscal year 2027, with profitability expected to increase thereafter, indicating the strategic value of the acquisition.
- Market Reaction: Medtronic's shares closed at $80.20 on Friday, down 0.16%, but traded slightly higher at $80.26 in the overnight market, reflecting a cautiously optimistic market response to the acquisition.
See More
Boston Scientific Stock Price Decline Analysis
- Poor Stock Performance: Boston Scientific (BSX) shares have fallen over 50% year-to-date, reflecting market disappointment with its growth expectations, particularly as management has repeatedly lowered guidance, undermining investor confidence.
- Guidance Downgrade: The management has revised its 2026 organic revenue growth forecast down to between 6.5% and 8%, and has indicated flat revenue growth for Q2 and Q3, raising concerns about the company's long-term investment appeal amid declining procedure usage.
- Analyst Optimism: Despite the bearish market sentiment, 27 out of 31 analysts still rate the stock as a buy, with a consensus price target of $78 per share, indicating a potential upside of 65%, which reflects analysts' confidence in the company's recovery potential.
- Valuation Challenges: Boston Scientific currently trades at a mid-teen forward valuation, comparable to other medical device firms like Abbott and Medtronic, and achieving a premium valuation will likely require a faster-than-expected recovery in growth, which appears challenging in the current market environment.
See More
Boston Scientific Shares Plunge Over 50% Amid Guidance Cuts
- Significant Stock Decline: Boston Scientific (NYSE: BSX) shares have plummeted over 50% year-to-date, primarily due to the company's ongoing downward revisions of its full-year 2026 guidance, which has severely undermined investor confidence and elicited a negative market response.
- Performance Guidance Adjustments: Management initially projected organic sales growth of 10% to 11% in February, but after reporting a 19.5% growth for 2025, investor reactions were poor, leading to further reductions in April and May, with 2026 organic revenue guidance now set between 6.5% and 8%.
- Analyst Sentiment Remains Positive: Despite the bearish market sentiment, 27 out of 31 analysts covering the stock still rate it as a buy, with a consensus price target of $78 per share, indicating a potential upside of 65%, reflecting analysts' confidence in the company's recovery prospects.
- Valuation Challenges Ahead: Boston Scientific currently trades at a forward valuation in the mid-teens, comparable to other medical device firms like Abbott and Medtronic, and achieving a premium valuation will likely require a faster-than-expected recovery in growth, which remains uncertain pending upcoming Q2 results and guidance.
See More
Medtronic Acquires Scientia Vascular to Enhance Neurovascular Technology
- Acquisition Scale: Medtronic has acquired Scientia Vascular, a private medical device company in Salt Lake City, for $550 million, subject to customary adjustments and potential undisclosed earn-out and milestone payments, further solidifying Medtronic's market position in the neurovascular sector.
- Integration Advantages: Scientia's guidewires and catheters can be seamlessly integrated with Medtronic's existing neurovascular products, enhancing physician efficiency in treating complex neurovascular conditions, simplifying procedural workflows, and improving patient treatment experiences.
- Market Demand Alignment: With stroke being the third leading cause of death globally, Scientia's innovative access platform aims to improve navigability through complex anatomy, enabling physicians to reach occlusions or aneurysms more quickly, thereby enhancing the timeliness and success of treatments.
- Financial Impact Outlook: The acquisition is expected to be minimally dilutive to Medtronic's adjusted EPS in FY27 but accretive thereafter, demonstrating Medtronic's ongoing commitment to pursuing high-growth opportunities and enhancing value for physician and hospital partners.
See More
Medtronic Acquires Scientia Vascular to Enhance Neurovascular Technology
- Acquisition Scale: Medtronic has acquired Scientia Vascular for $550 million, subject to customary adjustments, with potential undisclosed earn-out and milestone payments, reflecting Medtronic's ongoing expansion strategy in the healthcare technology sector.
- Integration Advantage: Scientia's guidewires and catheters can be seamlessly integrated with Medtronic's existing neurovascular products, enhancing physician efficiency in treating complex neurovascular conditions and further solidifying Medtronic's market leadership in this field.
- Improved Treatment Efficiency: Scientia's novel access platform addresses challenges posed by complex anatomy by improving navigability and simplifying neurovascular procedures, enabling faster treatment delivery and reducing brain cell loss due to delayed therapy, which has significant clinical implications.
- Financial Impact Outlook: The acquisition is expected to have a minimal dilutive effect on Medtronic's adjusted EPS in FY27 but is projected to become accretive thereafter, indicating a strategic decision to pursue high-growth opportunities that enhance value for stakeholders.
See More
SpaceX Sets Record with $75 Billion IPO, Aiming for 25-30% Opening Pop
- Historic IPO: SpaceX is conducting a record-breaking IPO today, raising up to $75 billion, with expectations of a 25-30% opening pop, which could attract short-term investors and potentially destabilize the company's shareholder base.
- Market Reaction: Oil prices have dropped over 3% to below $85 per barrel due to optimism surrounding a potential peace deal between the U.S. and Iran, indicating market sentiment ahead of next week's G7 Summit.
- Executive Changes: Adobe announced that CFO Dan Durn is leaving to join Marvell; despite beating earnings expectations, Adobe's stock fell 7%, reflecting market concerns about slowing growth.
- Analyst Rating Changes: Citi upgraded AMD from hold to buy, anticipating that Meta will significantly increase its purchases of AMD chips, indicating AMD's strengthening position in the graphics processing unit market as a legitimate competitor to Nvidia.
See More
